Insight Molecular Diagnostics price to sales ratio IMDX

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 55.5×
5-year median: 33.5×
Against its 5-year history: 77th; percentile: 0 is its lowest day, 100 its highest
5-year range: 3.8× to 199×
Peer median: 1.4×

Insight Molecular Diagnostics' price to sales ratio is 55.5× as of Oct 23, 2026.

That is above its 5-year median of 33.5×, higher than on 77% of days in the last 5 years.

Over that time it ranged from 3.8× in Mar 2023 to 199× in Jul 2021.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	55.5×	25.1×	106×
2025	41.5×	16.1×	92.6×
2024	50.1×	13.7×	64.3×
2023	5.1×	3.8×	7.2×
2022	4.7×	4.6×	40.9×
2021	43.1×	42.9×	199×

Against its peers

Companies in Healthcare nearest Insight Molecular Diagnostics' size, closest first, today.

Company	Price to sales ratio
IMDXInsight Molecular Diagnostics	55.5×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
APTAlpha Pro Tech	0.9×
ATNMActinium Pharmaceuticals	n/m
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
ELMDElectromed	3.0×
Peer median	1.4×

Where Insight Molecular Diagnostics ranks

#60of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Insight Molecular Diagnostics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.